Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling

Archives of Dermatology

Volumn 144, Issue 10, 2008, Pages 1341-1349

  Somani, Ally Khan ^a,b   Swick, Alan R ^a   Cooper, Kevin D ^a   McCormick, Thomas S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; CASE REPORT; DERMATOMYOSITIS; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SKIN BIOPSY; SYMPTOM; TREATMENT OUTCOME;

BIOPSY, NEEDLE; CELLS, CULTURED; DERMATOMYOSITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE I; INTERFERON-BETA; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 54349129097     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.10.1341     Document Type: Article

References (42)

1. Cervera R, Khamashta MA, Font J, et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299-308.
2. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41(1):22-26.
3. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-α/β- mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664-678.
4. Baechler EC, Batliwalla FM, Reed AM, et al. Gene expression profiling in human autoimmunity. Immunol Rev. 2006;210:120-137.
5. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther. 2003;5(6):279-287.
6. + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002;168(8):4154-4163.
7. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159(1):237-243.
8. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev. 2005;204:9-26.
9. Wenzel J, Wörenkämper E, Freutel S, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435-442.
10. +- lymphocytes in dermatomyositis. Clin Exp Dermatol. 2006;31(4):576-582.
11. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301(1):5-8.
12. Crispín JC, Díaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus. 2005;14(6): 495-496.
13. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol. 2000;17(1):64-69.
14. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307-336.
15. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet. 1998;352(9143):1825-1826.
16. Schmutz J, Barbaud A, Tréchot P. Subacute cutaneous lupus erythematosus and interferon beta-1a [in French]. Ann Dermatol Venereol. 2000;127(2):237.
17. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-139.
18. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med. 2006;84(11):901-910.
19. Applied Biosystems PE. User Bulletin #2: Relative Quantitation of Gene Expression. Foster City, CA: Applied Biosystems; 1977.
20. Fäh J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem. 1995;43(1):47-52.
21. Haller O, Kochs G. Interferon-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic. 2002;3(10):710-717.
22. Wenzel J, Uerlich M, Wörrenkämper E, Freutel S, Bieber T, Tüting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153(5):1011-1015.
23. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1-2):59-68.
24. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-2615.
25. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711-723.
26. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990;60 (2):225-234.
27. Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell. 1994;77(3):391-400.
28. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223-231.
29. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102 (9):3372-3377.
30. Wells J, Kossard S, McGrath M. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b. Australas J Dermatol. 2005; 46(3):202-204.
31. Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am. 2002;28(3):579-602, vii.
32. O'Connor KA, Abbott KA, Sabin B, Kuroda M, Pachman LM. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol. 2006;120(3):319-325.
33. De Paepe B, De Keyser KK, Martin JJ, De Bleecker JL. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol. 2005;109(6):576-582.
34. Avonex [package insert]. Cambridge, MA: Biogen Idec; 2005.
35. Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004;75(9):1294-1299.
36. Wenzel J, Scheler M, Bieber T, Tüting T. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br J Dermatol. 2005;153(2):462-463.
37. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferon-α in psoriatic T cells. J Invest Dermatol. 2005;125(5):936-944.
38. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003;36(8):511-518.
39. Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-β1a. J Interferon Cytokine Res. 2002;22(4): 491-501.
40. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275-306.
41. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005;97(15):1143-1153.
42. Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol. 2005;32(4):257-262.